Loxo Oncol Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LOXO ONCOL, and when can generic versions of LOXO ONCOL drugs launch?
LOXO ONCOL has two approved drugs.
There are nine US patents protecting LOXO ONCOL drugs.
There are one hundred and eighty-six patent family members on LOXO ONCOL drugs in forty-four countries and five supplementary protection certificates in four countries.
Summary for Loxo Oncol
| International Patents: | 186 |
| US Patents: | 9 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Loxo Oncol
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-002 | May 8, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-002 | May 8, 2020 | RX | Yes | Yes | 10,172,851 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-001 | Jan 27, 2023 | RX | Yes | No | 10,464,905 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | 10,172,851 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | 10,137,124 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-002 | May 8, 2020 | RX | Yes | Yes | 10,137,124 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-001 | Jan 27, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Loxo Oncol Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 3523302 | ⤷ Try a Trial |
| Ecuador | SP19032676 | ⤷ Try a Trial |
| Taiwan | 201922741 | ⤷ Try a Trial |
| Japan | 2021035944 | ⤷ Try a Trial |
| Australia | 2017342022 | ⤷ Try a Trial |
| Mexico | 2018007267 | ⤷ Try a Trial |
| Philippines | 12019500775 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Loxo Oncol Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3390395 | LUC00330 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PIRTOBRUTINIB; AUTHORISATION NUMBER AND DATE: EU/1/23/1738 20231031 |
| 3390395 | 301262 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 20231031 |
| 3390395 | CR 2024 00006 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PIRTOBRUTINIB; REG. NO/DATE: EU/1/23/1738 20231031 |
| 3390395 | PA2024506 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: PIRTOBRUTINIBAS; REGISTRATION NO/DATE: EU/1/23/1738 20231030 |
| 3390395 | CA 2024 00006 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PIRTOBRUTINIB; REG. NO/DATE: EU/1/23/1738 20231031 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
